Chemoradiation with novel agents for rectal cancer

Clinical Colorectal Cancer

Volumn 2, Issue 1, 2002, Pages 24-30

  McMullen, Kevin P ^a   Blackstock, A William ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab; COX 2 inhibitors; Gemcitabine; Irinotecan; Oxaliplatin; Radiation therapy; Topoisomerase inhibitors

Indexed keywords

CAMPTOTHECIN; CETUXIMAB; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX; PROSTAGLANDIN SYNTHASE INHIBITOR; RADIOSENSITIZING AGENT; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; FOLINIC ACID; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLATINUM DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DRUG ANTAGONISM; HUMAN; MULTIMODALITY CANCER THERAPY; RECTUM TUMOR; REVIEW; ADVANCED CANCER; BLOOD TOXICITY; CANCER CONTROL; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG UPTAKE; POSTOPERATIVE PERIOD; PREOPERATIVE RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; UNITED STATES; VOMITING;

ANTIBODIES, MONOCLONAL; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 0036018887     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2002.n.008     Document Type: Review

References (87)

1. Cancer Facts & Figures
2. Chemotherapy for colorectal cancer
3. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer
4. Postoperative radiation therapy for high-risk colon carcinoma
5. A phase III study of adjuvant radiation therapy (RT), 5-fluorouracil (5-FU), and levamisole (LEV) vs 5-FU and LEV in selected patients with resected high risk colon cancer: Initial results of Int 0130
6. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: A review of the Gastrointestinal Tumor Study Group experience
7. Effective surgical adjuvant therapy for high-risk rectal carcinoma
8. Adjuvant therapy for patients with colon and rectal cancer
9. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
10. Adjuvant radiation therapy of rectal cancer
11. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial
12. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis
13. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer
14. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro
15. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
16. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anti-cancer Drug Screen panel
17. Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroammines in Chinese hamster ovary cells
18. Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA
19. Ongoing and unsaid on oxaliplatin: The hope
20. Oxaliplatin is active in vitro against human melanoma cell lines: Comparison with cisplatin and carboplatin
21. Carboplatin as a potentiator of radiation therapy
22. Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells
23. Irradiation-enhanced binding of carboplatin to DNA
24. Toxic variability and radiation sensitization by Pt(II) analogs in Salmonella typhimurium cells
25. Irradiation enhances cellular uptake of carboplatin
26. Radiopotentiation by the oral platinum agent, JM216: Role of repair inhibition
27. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin
28. Oxaliplatin: In vitro and in vivo evidence of its radiation sensitizing activity - Pre-clinical observations relevant to ongoing clinical trials
29. Radiotherapy (Rx) combined with the association oxaliplatin (OXA) - 5 fluorouracil - Folinic acid (FUFA)
30. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
31. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy
32. Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 phase I trial
33. Chemoradiation with raltitrexed ('Tomudex') and oxaliplatin in pre-operative treatment of stage II/III resectable rectal cancer: A dose-finding study
34. A phase I dose escalation study of oxaliplatin when given in combination with 5-fluorouracil (5FU), low dose folinic acid (LDFA) and synchronous preoperative radiotherapy (RT) in locally advanced rectal cancer
35. Plant antitumor agents I. The isolation and structure of camptothecine, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata
36. Camptothecin induces protein-lined DNA breaks via mammalian DNA topoisomerase I
37. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
38. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
39. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development
40. Oral topoisomerase 1 inhibitors in adult patients: Present and future
41. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1 piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors
42. SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids
43. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives
44. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I
45. Daily low-dose irinotecan (CPT-11) plus pelvic irradiation as preoperative treatment of locally advanced rectal cancer
46. Combined mortality therapy of locally advanced or recurrent adenocarcinoma of the rectum: Report of a phase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT)
47. Phase II trial of preoperative radiotherapy, protracted venous infusion 5-fluorouracil and weekly CPT-11, followed by surgery for ultrasound staged T3/T4 rectal cancer
48. Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in rectal carcinoma. A phase I/II study
49. Preclinical characteristics of gemcitabine
50. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
51. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
52. Induction of apoptosis by gemcitabine
53. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
54. Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro
55. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
56. Radiosensitization of human tumor cells by gemcitabine in vitro
57. Radiosensitization produced in vivo by once- vs. twice-weekly 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
58. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
59. Phase II study of gemcitabine in advanced colorectal adenocarcinoma
60. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer
61. Phase I trial of topotecan (T) and gemcitabine (G) in solid tumor patients
62. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors
63. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities
64. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
65. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852
66. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
67. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
68. Epidermal growth factor receptor family and chemosensitization
69. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
70. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
71. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
72. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
73. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo
74. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
75. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
76. Increase in radioresponse of murine tumors by treatment with indomethacin
77. Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts
78. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse
79. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme
80. NF-kappa B signaling pathway as a target for human tumor radiosensitization
81. NF-kappa B and chemoresistance: Potentiation of cancer drugs via inhibition of NF-kappa B
82. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
83. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB
84. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition
85. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis
86. Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells
87. Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer